Liensinine alleviates LPS-induced acute lung injury by blocking autophagic flux via PI3K/AKT/mTOR signaling pathway - 11/11/23
![](/templates/common/images/mail.png)
Abstract |
Acute lung injury (ALI) is a major pathological problem characterized by severe inflammatory reactions and is a critical disease with high clinical morbidity and mortality. Liensinine, a major isoquinoline alkaloid, is extracted from the green embryos of mature Nelumbonaceae seeds. It has been reported to have an inhibitory effect on tumors. However, the effects of liensinine on ALI have not been reported to-date. The aim of this study was to explore the inhibitory effects of liensinine on lipopolysaccharide (LPS)-induced ALI and its possible mechanism. We found that liensinine significantly reduced LPS-induced ALI and reduced the production of inflammatory factors IL-6, IL-8, and TNF-α. In addition, liensinine blocked autophagic flux and increased the number of autophagosomes by upregulating LC3-II/I and p62 protein levels. More importantly, pretreatment with the early stages autophagy inhibitor 3-Methyladenine (3-MA) can reverse the inhibitory effects of liensinine on the secretion of inflammatory factors in ALI. The PI3K/AKT/mTOR pathway is involved in LPS-induced autophagy regulated by liensinine in ALI. In summary, this study suggests that liensinine inhibits the production of inflammatory factors in LPS-induced ALI by regulating autophagy via the PI3K/AKT/mTOR pathway, which may provide a new therapeutic strategy to alleviate ALI.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Liensinine alleviates lipopolysaccharide (LPS)-induced ALI in-vitro as well as in an ALI mouse model. |
• | Liensinine improved LPS-induced ALI by regulating and blocking autophagic flux. |
• | Liensinine inhibits the production of inflammatory factors by regulating autophagy via the PI3K/AKT/mTOR pathway. |
Abbreviations : ALI, ARDS, LPS, qPCR, LC3B, mTOR, 3-MA, BALF, ELISA
Keywords : Acute lung injury, Autophagic flux, Liensinine, PI3K/AKT/mTOR pathway
Plan
Vol 168
Article 115813- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?